icadmed.com (ICAD) - Pendapatan reged perusahaan

Total sales for iCAD, Inc. (ICAD) reflect the dynamics of an AI ecosystem for predictive breast cancer analysis, where 0.02 describes the current status of the metric. Growth is driven by subscriptions and partnerships with medtech giants. High barriers to entry are ensured by patents and FDA approval, which integrate the software into official medical protocols, making it difficult for new players to replicate the technologies.

Pendapatan lan volume dodolan: iCAD Corp (ICAD) kanggo 04.07.2022 - 02.08.2025

Rincian analitis perusahaan iCAD Inc. (ICAD)

- rega pasar lan target rega analis:

Rega bursa iCAD Corp|ICAD - Prakiraan konsensus analis

- indikator kapitalisasi pasar:

Kapitalisasi pasar iCAD, Inc.|ICAD - Nilai Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi saben Saham iCAD|ICAD - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku icadmed.com|ICAD - Total Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Rasio Utang marang Ekuitas iCAD, Inc.|ICAD - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal iCAD Corp|ICAD - Gunggung utang perusahaan|Utang-utang marang aset resik iCAD, Inc.|ICAD - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan iCAD|Indikator likuiditas cepet icadmed.com

- indikator profitabilitas perusahaan lan kelipatan valuasi:

ICAD - Penghasilan resik|Prakiraan bathi perusahaan iCAD, Inc.|ICAD - Pangali P/E|Kapitalisasi marang proyeksi bathi iCAD Corp|ICAD - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan iCAD, Inc.|ICAD - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) iCAD|ICAD - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan icadmed.com|ICAD - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep iCAD, Inc.

- statistik dodolan lan pendapatan perusahaan:

ICAD - Pendapatan lan volume dodolan|Prakiraan volume dodolan iCAD Corp|ICAD - Rasio rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan iCAD, Inc.

Ringkesan analisis perusahaan:iCAD, Inc.

Steady revenue growth confirms the fundamental stability of iCAD, Inc. (ICAD), while the company's sales performance is based on daily monitoring of operational liquidity to accurately calculate the control premium. This metric reflects the scaling efficiency of B2B subscriptions for ProFound AI platforms, allowing investors to assess the pace of software expansion across radiology centers and the capture of market share.

Analisis perusahaan pesaing